20/12/2025
Finding a ‘peek behind the curtain’ for CAR T-cell therapies may be the answer to new ways of treating solid cancer tumours.
CAR T-cell therapy has been a game-changer in treating blood cancers. Patient immune cells are modified to recognise cancer cells and attack them. Unfortunately, it has not been as successful in treating solid tumours. One potential reason is that not enough of the immune cells travel to the tumour to be effective. There is currently no method for locating and tracking these cells in real-time, making it hard to understand why CAR T-cell therapy is largely ineffective at treating solid tumours.
With the support of a Peter Mac Foundation Grant, Dr Rebecca Abbott is exploring if a molecule called a ‘tracer’ can be used to watch CAR T-cell therapy in action. This could potentially be a powerful tool in providing insights on why CAR T-cell therapy often doesn’t work in solid tumours, and how we can design CAR T-cells which are more effective.
Dr Abbott’s research can help to change the course for CAR T-cell therapy and expand treatment options across more cancer types. Thank you for supporting groundbreaking research that helps people with all cancers.